↓ Skip to main content

First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel

Overview of attention for article published in Frontiers in oncology, January 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel
Published in
Frontiers in oncology, January 2023
DOI 10.3389/fonc.2023.1117804
Pubmed ID
Authors

Itamar Averbuch, Saeed Salman, Noa Shtamper, Ilana Doweck, Aron Popovtzer, Gal Markel, Daniel Hendler, Inbar Finkel, Assaf Moore, Eyal Fenig, Tarek Taha, Kamel Mhameed, Noga Kurman, Salem Billan

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 1 9%
Unknown 10 91%
Readers by discipline Count As %
Psychology 1 9%
Social Sciences 1 9%
Medicine and Dentistry 1 9%
Unknown 8 73%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2023.
All research outputs
#16,063,069
of 25,394,764 outputs
Outputs from Frontiers in oncology
#5,648
of 22,436 outputs
Outputs of similar age
#231,398
of 472,368 outputs
Outputs of similar age from Frontiers in oncology
#326
of 1,393 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 472,368 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,393 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.